Lv3
280 积分 2024-01-06 加入
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer
2个月前
已完结
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma
3个月前
已完结
Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation
7个月前
已完结
Axicabtagene Ciloleucel in Large B-Cell Lymphoma
7个月前
已完结
Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population
7个月前
已完结
Clinical outcome and immunophenotype of axicabtagene ciloleucel (axi-cel) and relmacabtagene autoleucel (relma-cel) in relapsed/refractory large B-Cell lymphoma on Chinese population: a single-center experience
7个月前
已完结
Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis
7个月前
已完结
Chimeric Antigen Receptor T cells Immunotherapy: Challenges and Opportunities in Hematological Malignancies
8个月前
已完结
Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation
8个月前
已完结
Characterizing age-related differences in Hodgkin lymphoma in children, adolescents and young adults
8个月前
已完结
皖公网安备34019202002308
